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Abstract
Background: Endothelium-derived prostacyclin and nitric oxide elevate platelet cy-
clic nucleotide levels and maintain quiescence. We previously demonstrated that a 
synergistic relationship exists between cyclic nucleotides and P2Y12 receptor inhibi-
tion. A number of clinically approved drug classes can modulate cyclic nucleotide 
tone in platelets including activators of NO-sensitive guanylyl cyclase (GC) and phos-
phodiesterase (PDE) inhibitors. However, the doses required to inhibit platelets pro-
duce numerous side effects including headache.
Objective: We investigated using GC-activators in combination with P2Y12 receptor 
antagonists as a way to selectively amplify the anti-thrombotic effect of both drugs.
Methods: In vitro light transmission aggregation and platelet adhesion under flow 
were performed on washed platelets and platelet rich plasma. Aggregation in whole 
blood and a ferric chloride-induced arterial thrombosis model were also performed.
Results: The GC-activator BAY-70 potentiated the action of the P2Y12 receptor in-
hibitor prasugrel active metabolite in aggregation and adhesion studies and was 
associated with raised intra-platelet cyclic nucleotide levels. Furthermore, mice ad-
ministered sub-maximal doses of the GC activator cinaciguat together with the PDE 
inhibitor dipyridamole and prasugrel, showed significant inhibition of ex vivo platelet 
aggregation and significantly reduced in vivo arterial thrombosis in response to injury 
without alteration in basal carotid artery blood flow.
Conclusions: Using in vitro, ex vivo, and in vivo functional studies, we show that 
low dose GC activators synergize with P2Y12 inhibition to produce powerful anti-
platelet effects without altering blood flow. Therefore, modulation of intra-platelet 
cyclic nucleotide levels alongside P2Y12 inhibition can provide a strong, focused anti-
thrombotic regimen while minimizing vasodilator side effects.
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1  | INTRODUC TION
Platelets play a central role in cardiovascular disease, as they are 
integral to the development of acute thrombotic events. For this 
reason, anti-platelet therapy is prescribed for the secondary preven-
tion of atherothrombotic events in patients with acute coronary syn-
dromes or following percutaneous coronary intervention.1,2 Aspirin, 
which irreversibly inhibits the cyclooxygenase enzyme and down-
stream thromboxane (Tx)A2 production,
3,4 is often coadministered 
with a P2Y12 receptor antagonist, such as clopidogrel or prasugrel, to 
produce dual anti-platelet therapy (DAPT). P2Y12 receptor antago-
nists inhibit platelet aggregation by blocking the amplifying effects 
of adenosine diphosphate (ADP).5,6 While such therapy is effective, 
recurrent events still occur7,8 and alternative ways to prevent throm-
bosis continue to be required.
Vascular endothelial cells produce the short-lived autacoids 
prostaglandin I2 (prostacyclin; PGI2) and nitric oxide (NO) that 
relax blood vessels and inhibit platelets. PGI2 binds to platelet 
PGI2 (IP) receptors that in turn activate adenylyl cyclase (AC) to 
increase intracellular cyclic adenosine monophosphate (cAMP) 
levels.9 In contrast, NO diffuses freely into platelets activating the 
α1β1 isoform of guanylyl cyclase (GC-1, formerly known as soluble 
GC)10 to increase intracellular cyclic guanosine monophosphate 
(cGMP) levels.11 This intra-platelet elevation of levels of individual 
cyclic nucleotides is synergistic in maintaining basal platelet qui-
escence and preventing inappropriate platelet activation.12 Drugs 
targeting the NO-cGMP pathway, such as organic nitrates, are 
long established clinically for treatment of heart failure and angina 
pectoris.13 In recent years, drugs which directly activate or stim-
ulate GC have been developed as potential vasodilators and have 
been clinically approved for the treatment of pulmonary vascular 
disease.14 Similarly, drugs which modulate the cAMP pathway such 
as phosphodiesterase (PDE) inhibitors and PGI2 analogues are ap-
proved for the treatment of peripheral and pulmonary vascular 
disease. However, the doses of cyclic nucleotide elevating drugs 
that produce anti-platelet effects are associated with side effects 
such as headache, nausea, and hypotension.15,16 This is consis-
tent with the doses required to inhibit platelets being the same as 
those that produce vasodilatation.
We have recently demonstrated that blockade of platelet P2Y12 
receptor further synergizes with PGI2 and NO
17,18 to produce pro-
found platelet inhibition. We therefore hypothesized that the ac-
tions of pharmacological agents acting upon cyclic nucleotides could 
be selectively amplified in platelets by combination with P2Y12 re-
ceptor antagonists, thereby producing an enhanced anti-platelet 
effect of both drugs at doses which do not produce systemic vasodi-
lator side effects. Here we report in vitro, ex vivo, and in vivo studies 
that support this hypothesis.
2  | METHODS
2.1 | Blood collection and isolation of human 
platelets
Use of human blood samples was approved by St Thomas's Hospital 
Research Ethics Committee (Ref. 07/Q0702/24) and all studies were 
conducted in accordance with the Declaration of Helsinki. Blood 
was obtained by venipuncture from the median cubital vein using a 
19G butterfly needle into tri-sodium citrate (0.32% w/v final; Sigma, 
UK). Blood from healthy volunteers free of antiplatelet drugs was 
centrifuged at 180 × g for 15 minutes to obtain platelet-rich-plasma 
(PRP). Where appropriate, washed platelets (WP) were isolated from 
PRP by further centrifugation (1000 × g, 10 minutes) in the pres-
ence of PGI2 (1 µg/mL; Tocris) and apyrase (0.02 U/mL; Sigma). The 
resulting pellet was washed in modified Tyrode's (MTH) buffer (con-
taining 134 mmol/L NaCl, 2.9 mmol/L KCl, 0.34 mmol/L Na2HPO4, 
12 mmol/L NaHCO3, and 1 mmol/L MgCl2; pH 7.4) containing 
HEPES (20 mmol/L; Sigma) and 0.02 U/mL apyrase (Sigma) and re-
suspended in MTH buffer to a concentration of 3 × 108 platelets/mL.
Washed platelets, PRP, or whole blood were treated either with 
vehicle (0.5% DMSO), P2Y12 receptor antagonist prasugrel active 
metabolite (PAM; kind gift from AstraZeneca), ARC66096 tetraso-
dium (Tocris), and/or GC-1 activator BAY 60-2770 (BAY-70; kind gift 
from Dr Johannes-Peter Stasch, Bayer AG) for 30 minutes at 37°C.
2.2 | Mouse strains
C57Bl/6 wild-type (WT) mice were purchased from Charles River 
UK. All mice were 8 to 12 weeks old (20-25 g) and housed for a 
minimum of 7 days before commencement of experiments. They 
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Essentials
• A synergistic relationship exists between cyclic nucleo-
tides and P2Y12 receptor inhibition.
• Approved drugs that modulate cyclic nucleotide tone 
in platelets produce numerous side effects including 
headache.
• Low dose guanylyl cyclase activators synergize with 
P2Y12 inhibition to produce a powerful anti-platelet ef-
fect without altering blood flow.
• This novel combination can provide a strong and fo-
cused anti-thrombotic regimen.
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were housed on a 12-hour light-dark cycle, at a temperature of 22 
to 24°C with access to water and food ad libitum. Animal procedures 
were conducted under UK Home Office project license authority 
(PPL/8422) in accordance with “The Animals (Scientific Procedures) 
Act 1986,” EU directive 2010/63/EU, and were subject to local ap-
proval from Queen Mary University of London and Imperial College 
London Ethical Review Panels.
2.3 | Mouse dosing and obtaining blood
To maximize clinical relevance in vivo we replaced PAM with prasu-
grel and BAY-70 with cinaciguat (BAY 58-2667, kind gift from Bayer 
AG), as both are approved for human administration. However, given 
the short half-life of intra-platelet cyclic nucleotides we coadminis-
tered the clinically used PDE inhibitor dipyridamole so as to maxi-
mize the detection of anti-platelet effects ex vivo. In total four test 
groups were conducted: (a) vehicle alone; (b) prasugrel alone; (c) 
cinaciguat and dipyridamole; or (d) prasugrel, cinaciguat, and dipy-
ridamole together (combined therapy).
Prasugrel (0.3 mg/kg, Sigma) or vehicle (0.6% DMSO) intrave-
nous plus dipyridamole (2 mg/kg; Sigma) or vehicle (0.03% v/v HCl) 
intraperitoneal was administered 2 hours prior to blood collection or 
arterial injury. Mice were subsequently anesthetized with ketamine 
(Narketan, 100 mg/kg; Vetoquinol) and xylazine (Rompun, 10 mg/
kg; Bayer, Germany) intraperitoneal cinaciguat (0.3 mg/kg) or vehicle 
(2% DMSO) intravenous was administered 10 minutes prior to blood 
collection or arterial injury. Blood was collected from the inferior 
vena cava into trisodium citrate (0.32%).
2.4 | Light transmission aggregometry
Aggregation in response to collagen (10 µg/mL, Horm collagen; 
Nycomed), thrombin (1 U/mL, Sigma), or thrombin receptor activat-
ing peptide SFLLRN (30 µmol/L, TRAP-6, Bachem) was measured by 
light transmission aggregometry (LTA) in a Bio/Data PAP-8E turbi-
dometric aggregometer (Alpha Laboratories). Percent final aggrega-
tion, or percent inhibition of final aggregation values after 5 minutes 
are reported.
2.5 | Platelet adhesion under physiological flow
Flow chamber slides (VI0.1 µ-slide, Ibidi) were coated with Horm 
collagen (100 µg/mL) followed by blocking with bovine serum 
albumin (BSA, 4%, Sigma). Whole blood, treated with mepacrine 
(10 µmol/L, Sigma) to label platelets, was perfused across the 
coated surface at 1000 s−1 for 5 minutes. Post-flow images were 
taken (four per experiment) at x40 magnification using a TE-2000S, 
Nikon Eclipse inverted microscope connected to a RT slider CCD 
camera (Diagnostic Instruments Inc). Images were analyzed using 
Image J (NIH).
2.6 | Whole blood aggregation
Aggregation was conducted as we have previously described.19 
Half-area 96-well microtiter plates (Greiner Bio-One, UK) were 
pre-coated with hydrogenated gelatin (0.75% w/v; Sigma) in phos-
phate-buffered saline to block nonspecific activation of blood. 
Horm collagen (10 µg/mL), TRAP-6 (30 µmol/L), the PAR-4 activat-
ing peptide AYPGKF amide (PAR4-amide, 30 µmol/L; Bachem), or 
the TxA2 mimetic U46619 (3 µmol/L; Cayman Chemical Company) 
were freeze-dried onto the plate and the plates vacuum sealed until 
needed.
At the time of experiment whole blood was placed into each well 
and aggregation stimulated by placing the plate on a heated plate 
shaker (Bioshake IQ, Q Instruments) at 37°C, mixing at 1200 rpm, for 
5 minutes. The single platelet counts of each well were determined 
by flow cytometry. Human platelets were labelled with allophyco-
cyanin (APC) conjugated anti-CD61 monoclonal antibody (clone VI-
PL2, Life Technologies) for 30 minutes. Alternatively, mouse platelets 
were labelled using APC-conjugated anti-CD41 monoclonal anti-
body (clone MWReg30, Life Technologies) for 30 minutes. Samples 
were then diluted in phosphate buffered saline containing 0.1% for-
malin (Sigma), 0.1% dextrose (Sigma), and 0.2% BSA before addition 
of 104 CountBright™ absolute counting beads (Life Technologies). 
Labelled, diluted blood was then analyzed using a FACSCalibur flow 
cytometer (BD Biosciences).
2.7 | Mouse ferric chloride arterial injury
In mice anesthetized with ketamine and xylazine, the carotid artery 
was exposed and isolated from surrounding tissues to permit a ferric 
chloride (FeCl3, 10% solution, Sigma) soaked filter paper to be ap-
plied for 3 minutes. The carotid artery was then flooded with saline 
and the filter paper removed. A Doppler flow probe (Transonic) was 
then placed around the artery and flow monitored for up to 30 min-
utes. The time to stable occlusion (defined as flow 0.0 ± 0.2 mL/min 
for 1 minute) was recorded.
2.8 | Mouse tail bleeding assay
Anesthetized mice were maintained at 37°C and their tail was tran-
sected with a scalpel blade at 1 mm from its end. The tail was im-
mersed immediately in warm saline (37°C) and time recorded until it 
stopped bleeding for 30 seconds.
2.9 | Statistics and data analysis
Parametric data presented as mean ± standard error of the 
mean (SEM). Statistical analysis was performed using Prism 6.0 
(GraphPad software). Significance was determined by one-way 
analysis of variance (ANOVA) with Dunnett's post-hoc test unless 
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otherwise stated, and data sets considered different if P < .05. For 
non-parametric data significance was determined by Mantel-Cox 
test and with Holm-Sidak correction for multiple comparisons 
where necessary. Flow cytometry data was analyzed using FlowJo 
v7.4 (Tree Star). For analysis, the “single platelet” population was 
gated based on side scatter and anti-platelet immunoreactivity 
(fluorescence intensity).
3  | RESULTS
3.1 | BAY-70 potentiates the inhibitory action of 
PAM in washed platelets and PRP in a concentration-
dependent manner
Aggregation responses to thrombin were first established in 
WP (Figure 1A,B). A threshold concentration of PAM (3 µmol/L) 
that had little inhibitory effect when used alone was determined 
(64 ± 1% vehicle versus 59 ± 1% PAM, P > .05). Increasing con-
centrations of the GC-1 activator BAY-70 produced concentration-
dependent potentiation of the inhibitory effect of PAM. At the 
maximum tested concentration of BAY-70 (10 µmol/L) in presence 
of PAM, aggregation was reduced by 54 ± 4% (P < .05). The same 
concentration of BAY-70 in the absence of PAM had little inhibi-
tory action, with aggregation being reduced by 7 ± 3% (P > .05). 
A similar pattern was seen in experiments examining collagen-
induced aggregation (Figure 1B). Interestingly, in these conditions 
BAY-70 achieved a 65 ± 4% decrease at the far lower concentra-
tion of 10 nmol/L in the presence of PAM, compared to a 17 ± 5% 
decrease without PAM (P < .05).
In experiments using PRP, thrombin was replaced by the acti-
vator peptide TRAP-6. As in WP, PAM 3 µmol/L had little effect 
on TRAP-6 induced aggregation (77 ± 10% vehicle; 70 ± 8% PAM; 
Figure 1C,D). Similarly, BAY-70 potentiated the effect of PAM against 
both TRAP-6 and collagen. Aggregation (Figure 1D) conducted in the 
presence of 10 µmol/L BAY-70 plus PAM were inhibited by 55 ± 10% 
and 76 ± 11% when induced by TRAP-6 and collagen, respectively, 
compared to 15 ± 3% and 28 ± 5%, respectively, when PAM was not 
present (P < .05 versus BAY-70 plus PAM). In a separate mechanistic 
study (Figure S1 in supporting information) we found that PAR4, as 
compared to PAR1, agonism was more sensitive to P2Y12 antagonism 
in the presence of BAY-70.
F I G U R E  1    Guanylyl cyclase (GC-1) activator BAY-70 potentiates anti-platelet actions of the P2Y12 inhibitor prasugrel active metabolite 
(PAM) in vitro. A, Representative light transmission aggregometry (LTA) trace of aggregation in response to thrombin (1 U/mL) of washed 
platelets treated with BAY-70 (1 µmol/L) and/or PAM (3 µmol/L). B, Concentration inhibitor curves (as % of final aggregation after 5 minutes) 
for BAY-70 in presence of vehicle or PAM against aggregation induced by thrombin or collagen (10 µg/mL). C, Representative LTA trace of 
aggregation to TRAP-6 (30 µmol/L) of platelet-rich plasma (PRP) treated with BAY-70 (10 µmol/L) and/or PAM (3 µmol/L). D, Concentration 
inhibitor curves (as % of final aggregation after 5 minutes) for BAY-70 in presence of vehicle or PAM against aggregation induced by TRAP-6 
or collagen (10 µg/mL). Data presented as mean ± standard error of the mean. *P < .05 by two-way analysis of variance, n = 4 for all
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3.2 | BAY-70 potentiates the anti-thrombotic 
action of PAM in whole blood
Similar data were obtained in whole blood assays. In studies of 
whole blood platelet adhesion under flow, BAY-70 and PAM when 
used individually produced similar reductions in platelet coverage 
from 9.8 ± 2.6% (vehicle) to 5.4 ± 1.1% and 5.5 ± 0.9%, respectively. 
Combination of BAY-70 and PAM together caused a further reduc-
tion of coverage to 2.3 ± 0.5% (P < .05 versus vehicle; Figure 2A,B).
Aggregation in whole blood stimulated by TRAP-6 was deter-
mined by flow cytometry. In this assay, neither BAY-70 nor PAM 
alone had any inhibitory effect (final aggregations of 76 ± 8% vehicle 
versus 84 ± 4% and 76 ± 4% respectively, P > .05). In contrast BAY-
70 and PAM strongly combined to reduce aggregation by 71 ± 7% 
(P < .05 versus vehicle; Figure 2C).
3.3 | Cyclic nucleotide modulators potentiate the 
inhibitory action of prasugrel in vivo
Having established that the GC-1 activator BAY-70 potentiates the 
anti-platelet effect of PAM we next sought to investigate if this can 
occur and is relevant in vivo.
Following in vivo drug administration, ex vivo platelet aggrega-
tion studies demonstrated no significant inhibitory effects of either 
prasugrel alone or the combination of two cyclic nucleotide elevating 
drugs—the GC-1 activator cinaciguat plus the PDE inhibitor dipyrid-
amole (Figure 3A-C) at the selected doses. In contrast, platelets in 
blood from mice that had received the combination prasugrel with 
cinaciguat plus dipyridamole demonstrated significantly lower ag-
gregatory responses than those from vehicle treated animals (colla-
gen, 22 ± 9% versus 53 ± 9%; PAR-4 peptide, 7 ± 4% versus 37 ± 9%; 
U46619, 13 ± 6% versus 48 ± 11%; P < .05 for all).
In the FeCl3-induced arterial thrombosis injury model prasu-
grel alone (time to occlusion, 438 ± 87 seconds) or cinaciguat plus 
dipyridamole (482 ± 110 seconds) had no effect relative to vehicle 
(432 ± 50 seconds). In contrast, the combination of all three caused 
a significant increase in the time to occlusion (P < .01) with only two 
of six mice fully occluding within 30 minutes. Consistent with these 
results we also observed a significantly extended bleeding time 
(P < .01) in a tail transection model. No differences in blood flow in 
the carotid artery immediately prior to injury were noted (vehicle, 
0.7 ± 0.1 mL/min; prasugrel alone, 0.8 ± 0.1 mL/min; cinaciguat plus 
dipyridamole, 0.8 ± 0.1 mL/min; combination therapy, 0.9 ± 0.1 mL/
min) demonstrating that at the doses used the drugs did not cause 
systemic vasodilation alone or in combination.
F I G U R E  2    Guanylyl cyclase (GC-1) 
activator BAY-70 potentiates inhibition 
by prasugrel active metabolite (PAM) 
of platelet adhesion and aggregation in 
whole blood. A, Representative images 
of platelet (green) adhesion to collagen 
(100 µg/mL) following perfusion (1000 s−1 
for 5 minutes). Images acquired at ×40 
magnification using a Nikon TE-2000S 
inverted microscope. B, Quantification of 
area covered (%, n = 6). C, Aggregation 
(%, n = 7) in whole blood in response to 
TRAP-6 (30 µmol/L) using flow cytometry. 
Data presented as mean ± standard error 
of the mean. **P < .01 versus vehicle by 
paired analysis of variance
Vehicle BAY-70 
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4  | DISCUSSION
Here we demonstrate that cyclic nucleotide level modulators can 
preferentially target platelets through combination with P2Y12 re-
ceptor antagonists. In all experiments we observed potentiation 
of the effects of PAM or prasugrel using direct GC-1 activation. 
Importantly, this combination of multiple drugs achieved anti-plate-
let protection using lower concentrations or doses that were inef-
fective individually and which did not cause systemic vasodilation 
in vivo.
In our in vitro experiments we observed this combinatorial ef-
fect against both adhesion and aggregation of platelets. Moreover, 
we established that this effect is maintained across a range of envi-
ronments, from washed platelet preparations to platelet rich plasma 
or anti-coagulated whole blood. Finally, we translated our findings 
toward the clinic by demonstrating the combinatorial effect was dis-
played in ex vivo whole blood aggregation and in in vivo thrombo-
sis models in mice that had received clinical formulations of these 
therapeutics.
Currently patients at risk of coronary thrombotic events re-
ceive a dual anti-platelet regimen consisting of aspirin plus a P2Y12-
receptor antagonist such as clopidogrel or prasugrel.20,21 However, 
research efforts continue to identify the optimal combination of ex-
isting medications. One aspect, assessed in studies such as GLOBAL 
LEADERS and TWILIGHT,22,23 is whether aspirin is essential as a 
baseline therapy. We have previously described how in the presence 
of strong P2Y12 receptor blockade, addition of aspirin could produce 
a net pro-thrombotic effect and so potentially a reduction in clinical 
efficacy.24-26 An alternative therefore is to use P2Y12 antagonists as 
a baseline therapy with the addition of anti-thrombotic drugs acting 
upon other pathways. Because the effects of P2Y12 receptor antag-
onists in vivo may be, at least partly, dependent upon the presence 
of the endothelial autacoids NO and PGI2,
27 their clinical effective-
ness could well be reduced in patients with endothelial dysfunction, 
which is an early event in the pathophysiology of cardiovascular dis-
ease.28 During endothelial dysfunction NO and PGI2 production will 
be reduced, leading to reduced intra-platelet cyclic nucleotide tone 
and so increased platelet reactivity. Therefore, it may well be those 
patients with the greatest level of endothelial dysfunction that get 
the smallest benefit from adequate P2Y12 inhibition. Indeed, we re-
cently reported that the P2Y12 inhibitor ticagrelor attenuated plate-
let function more potently in samples from well-trained middle-aged 
men with a superior vascular function compared to matched un-
trained men with a reduced vascular function.29
A logical extension of the argument above is that drug therapy to 
increase intra-platelet cyclic nucleotides would boost the anti-plate-
let effect of P2Y12 antagonists. There exist a number of agents avail-
able to modulate cyclic nucleotide levels; however, we chose to focus 
F I G U R E  3    Guanylyl cyclase (GC-1) 
activator cinaciguat, in combination with 
dipyridamole, potentiates the inhibitory 
effects of prasugrel against ex vivo 
aggregation and in vivo thrombosis in 
mice. A, Aggregation in whole blood in 
response to collagen (10 µg/mL), PAR-4 
amide (30 µmol/L), and TxA2 mimetic 
U46619 (3 µmol/L). *P < .05 versus 
vehicle, n = 5-7 per group. B, Kaplan Meier 
plot for occlusion against time (minutes) 
following FeCl3-induced arterial injury in 
mice. **P < .01 versus vehicle by Mantel-
Cox test with Holm-Sidak correction, 
n = 6 per group. C, Kaplan Meier plot 
of bleeding against time for vehicle and 
combined treatment groups. **P < .01 
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upon the relatively recently developed direct GC-1 activators30 in 
combination with standard drugs already used for anti-thrombotic 
prophylaxis. These GC-1 activators directly act upon NO-sensitive 
GC to stimulate cGMP production without the requirement of NO 
or the heme moiety,31 the separation of which can occur during en-
dothelial dysfunction and oxidative stress.14
Our initial in vitro experiments were completed using the com-
pound BAY-70 as a pharmacological tool, which is effective at rais-
ing cGMP levels.32 Notably it has also previously been reported 
that BAY-70, in the micro-molar range, can inhibit washed platelet 
activation.33 In our experiments in washed platelet preparations, na-
no-molar concentrations were sufficient to inhibit platelet activation 
in the presence of PAM.
For the in vivo studies we chose to use the related compound 
cinaciguat. Cinaciguat has previously been studied in a phase IIb 
clinical trial in patients with acute decompensated heart failure,15 
and therefore has potentially more clinical relevance. We also 
opted to include dipyridamole as a PDE inhibitor with the intention 
to prolong cyclic nucleotide tone and thus detect their influence 
ex vivo. Dipyridamole has historically been prescribed combined 
with aspirin as anti-thrombotic therapy for patients who have had 
an ischemic stroke. Its use, however, like that of other drugs tar-
geting cyclic nucleotides modulation, is associated with localized 
or systemic vasodilation16 due to effects on the vascular smooth 
muscle. In our study, we administered lower doses of cinaciguat 
and dipyridamole as we hypothesized that in the presence of plate-
let P2Y12 receptor blockade there would be a synergistic focus 
of effects upon platelet function and away from the vasculature 
(Figure 4A-C). Indeed, we did not observe any significant change 
to arterial blood flow in our in vivo studies in any of our treatment 
groups while observing clear anti-thrombotic effects only in our 
combined treatment group.
While our study primarily centered upon directly activating NO-
sensitive GC, the physiology of the synergy resulting in increased 
P2Y12 efficacy means that this could realistically be achieved using 
alternative clinically available agents targeting a number of pathways 
to equally modulate cyclic nucleotide tone. For example, the related 
compound riociguat, approved for use in pulmonary hypertension, 
acts by a related mechanism of stimulating, rather than activating, 
GC-1. Alternatively, selexipag, approved for use in pulmonary arte-
rial hypertension,34 acts as an agonist of the PGI2 IP receptor and 
stimulates AC-dependent cAMP production.35 Equally, selective 
PDE isoform inhibitors, such as cilostazol, which targets PDE3 and 
is used in the management of intermittent claudication, may be ef-
fective for the targeted prolongation of platelet cyclic nucleotide 
half-life.
Another important component of this study is that the concen-
trations or doses of BAY-70 or cinaciguat, PAM or prasugrel, and 
dipyridamole used had little functional effect when used on their 
own. This means that it may be possible to achieve therapeutic ef-
fectiveness using lower doses than those currently prescribed for 
individual use and so reducing drug-associated side effects.
In conclusion, our study builds upon our previous observations 
of a synergistic relationship between P2Y12 receptor inhibition 
and platelet cyclic nucleotide levels to identify a novel poten-
tial anti-platelet drug regimen. We demonstrate the principle of 
a combination of low doses of approved drugs targeted at cyclic 
nucleotide modulation, combined with P2Y12 inhibition, as a re-
alistic and powerful therapeutic regimen. While more work and 
optimization will be required to clinically translate this in human 
F I G U R E  4   Summary of the pathophysiological rationale for the efficacy of combined cyclic nucleotide modulators with P2Y12 receptor 
antagonists as anti-platelet therapy. A, In the healthy circulation endothelial-derived mediators nitric oxide (NO) and prostaglandin I2 
(PGI2) act upon platelets to raise cyclic nucleotide (cAMP and cGMP) levels that in turn maintain platelets in a quiescent state. B, During 
established cardiovascular disease, concurrent endothelial dysfunction results in reduced production of NO and PGI2, lowering intra-platelet 
cyclic nucleotide tone and decreasing the threshold for activation. C, A synergic relationship exists between intra-platelet cyclic nucleotides 
and P2Y12 receptor blockade such that pharmacological modulators of cyclic nucleotides, to compensate for reduced endothelial cell 
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studies, such combined pharmacological approaches represent a 
focused anti-platelet regimen while potentially sparing associated 
off-target side effects.
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